AMG 706

DRUG16 trials

Sponsors

Amgen, Eastern Cooperative Oncology Group

Conditions

Advanced Gastrointestinal Stromal TumorAdvanced Non-squamous NSCLCAdvanced Solid TumorsBreast CancerBreast NeoplasmsBreast TumorsColon CancerEsophageal Cancer

Phase 1

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

CompletedNCT00093873

Start: 2003-07-31End: 2006-12-31Updated: 2013-05-15

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

CompletedNCT00101894

AmgenColon Cancer, Rectal Cancer

Start: 2004-12-31End: 2011-12-31Updated: 2012-09-17

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

TerminatedNCT00101907

AmgenEsophageal Cancer, Lung Cancer, Pancreatic Cancer

Start: 2004-12-31End: 2008-04-30Updated: 2014-03-20

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

CompletedNCT00322400

AmgenLocally Recurrent and Metastatic Breast Cancer

Start: 2006-03-31End: 2012-01-31Updated: 2013-07-31

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

CompletedNCT00448786

AmgenSolid Tumors

Start: 2007-02-28End: 2009-03-31Updated: 2011-01-21

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

CompletedNCT00861419

AmgenAdvanced Solid Tumors

Start: 2005-12-31Target: 88Updated: 2017-02-08

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

CompletedNCT01235416

AmgenHistologically or Cytologically Documented Solid Tumors

Start: 2005-09-30End: 2010-02-28Updated: 2011-01-21

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

CompletedNCT01386866

AmgenAdvanced Solid Tumors

Start: 2009-05-31End: 2010-12-31Updated: 2011-07-15

Phase 2

Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)

CompletedNCT00089960

AmgenGastrointestinal Cancer

Start: 2004-10-31End: 2008-06-30Updated: 2013-04-29

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

CompletedNCT00121628

AmgenThyroid Cancer

Start: 2005-07-31End: 2010-10-31Updated: 2013-10-09

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

CompletedNCT00254267

AmgenAdvanced Gastrointestinal Stromal Tumor

Start: 2005-11-30End: 2012-12-31Updated: 2014-02-27

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

TerminatedNCT00356681

AmgenBreast Cancer, Breast Neoplasms, Breast Tumors +1

Start: 2006-12-31End: 2012-08-31Updated: 2015-10-15

An Open Label Treatment Extension Study of AMG 706

TerminatedNCT00360867

AmgenSolid Tumors

Start: 2005-12-31End: 2012-07-31Updated: 2015-10-15

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

TerminatedNCT00369070

AmgenAdvanced Non-squamous NSCLC

Start: 2007-01-31End: 2011-08-03Updated: 2018-01-04

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

CompletedNCT00427349

Eastern Cooperative Oncology GroupGastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome

Start: 2008-11-07End: 2015-04-30Updated: 2023-07-05

Phase 3

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

TerminatedNCT00460317

AmgenNon-Small Cell Lung Cancer

Start: 2007-07-31End: 2013-08-31Updated: 2015-09-07

Related Papers

Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience

PLoS ONE2014-10-147 citations

Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.

2014-01-1314 citations

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.

2013-05-169 citations

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

2011-07-268 citations

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

2011-03-2160 citations

Motesanib diphosphate in progressive differentiated thyroid cancer.

2008-07-01321 citations